Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1980 1
1983 4
1984 2
1986 1
1987 2
1988 1
1989 1
1990 1
1991 1
1993 1
1994 1
1996 1
1998 2
1999 3
2002 3
2003 3
2004 1
2005 2
2006 4
2007 2
2008 7
2009 4
2010 8
2011 12
2012 9
2013 8
2014 8
2015 13
2016 8
2017 10
2018 14
2019 16
2020 15
2021 11
2022 9
2023 9
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Results by year

Filters applied: . Clear all
Page 1
Diagnostic yield of genetic testing in a heterogeneous cohort of 1376 HCM patients.
Hathaway J, Heliö K, Saarinen I, Tallila J, Seppälä EH, Tuupanen S, Turpeinen H, Kangas-Kontio T, Schleit J, Tommiska J, Kytölä V, Valori M, Muona M, Sistonen J, Gentile M, Salmenperä P, Myllykangas S, Paananen J, Alastalo TP, Heliö T, Koskenvuo J. Hathaway J, et al. BMC Cardiovasc Disord. 2021 Mar 5;21(1):126. doi: 10.1186/s12872-021-01927-5. BMC Cardiovasc Disord. 2021. PMID: 33673806 Free PMC article.
BACKGROUND: Genetic testing in hypertrophic cardiomyopathy (HCM) is a published guideline-based recommendation. ...RESULTS: A total of 1376 samples were analyzed. Three hundred and sixty-nine tests were diagnostic (26.8%); 373 P or LP variants were identified …
BACKGROUND: Genetic testing in hypertrophic cardiomyopathy (HCM) is a published guideline-based recommendation. ...RESULTS: A …
Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines.
Wang J, Yang S, Ma X, Zhao K, Yang K, Yu S, Yin G, Dong Z, Song Y, Cui C, Li J, Wang C, Hao J, Lu M, Chen X, Zhao S. Wang J, et al. Eur Heart J. 2023 Dec 1;44(45):4781-4792. doi: 10.1093/eurheartj/ehad581. Eur Heart J. 2023. PMID: 37795986
BACKGROUND AND AIMS: Identifying patients with hypertrophic cardiomyopathy (HCM) who are candidates for implantable cardioverter defibrillator (ICD) implantation in primary prevention for sudden cardiac death (SCD) is crucial. ...Patients suffering from SCD had high …
BACKGROUND AND AIMS: Identifying patients with hypertrophic cardiomyopathy (HCM) who are candidates for implantable cardiovert …
Genotype-Phenotype Taxonomy of Hypertrophic Cardiomyopathy.
Curran L, de Marvao A, Inglese P, McGurk KA, Schiratti PR, Clement A, Zheng SL, Li S, Pua CJ, Shah M, Jafari M, Theotokis P, Buchan RJ, Jurgens SJ, Raphael CE, Baksi AJ, Pantazis A, Halliday BP, Pennell DJ, Bai W, Chin CWL, Tadros R, Bezzina CR, Watkins H, Cook SA, Prasad SK, Ware JS, O'Regan DP. Curran L, et al. Circ Genom Precis Med. 2023 Dec;16(6):e004200. doi: 10.1161/CIRCGEN.123.004200. Epub 2023 Nov 28. Circ Genom Precis Med. 2023. PMID: 38014537 Free PMC article.
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is an important cause of sudden cardiac death associated with heterogeneous phenotypes, but there is no systematic framework for classifying morphology or assessing associated risks. ...METHODS: We enrolled 436 patients …
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is an important cause of sudden cardiac death associated with heterogeneous phen …
Utility of genetic testing in athletes.
Gray B, Semsarian C. Gray B, et al. Clin Cardiol. 2020 Aug;43(8):915-920. doi: 10.1002/clc.23289. Epub 2020 Jan 11. Clin Cardiol. 2020. PMID: 31925963 Free PMC article. Review.
Most inherited cardiac conditions have an underlying genetic basis to disease and genetic testing in an athlete can have diagnostic, prognostic and therapeutic implications, including guiding exercise recommendations. ...
Most inherited cardiac conditions have an underlying genetic basis to disease and genetic testing in an athlete can have diagnostic, prognos …
Genetic profile and genotype-phenotype correlations in childhood cardiomyopathy.
Wanert C, El Louali F, Al Dybiat S, Nguyen K, Zaffran S, Ovaert C. Wanert C, et al. Arch Cardiovasc Dis. 2023 Jun-Jul;116(6-7):309-315. doi: 10.1016/j.acvd.2023.04.008. Epub 2023 May 16. Arch Cardiovasc Dis. 2023. PMID: 37246080 Free article.
RESULTS: Eighty-three patients were included between 2005 and 2019. Most patients had hypertrophic cardiomyopathy (39.8%) or dilated cardiomyopathy (27.7%). ...CONCLUSIONS: In our population, children with cardiomyopathy had a high positive gene …
RESULTS: Eighty-three patients were included between 2005 and 2019. Most patients had hypertrophic cardiomyopathy (39.8 …
Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy.
Bonaventura J, Rowin EJ, Chan RH, Chin MT, Puchnerova V, Polakova E, Macek M Jr, Votypka P, Batorsky R, Perera G, Koethe B, Veselka J, Maron BJ, Maron MS. Bonaventura J, et al. J Am Heart Assoc. 2024 May 21;13(10):e033565. doi: 10.1161/JAHA.123.033565. Epub 2024 May 17. J Am Heart Assoc. 2024. PMID: 38757491 Free PMC article.
BACKGROUND: The genetic basis of hypertrophic cardiomyopathy (HCM) is complex, and the relationship between genotype status and clinical outcome is incompletely resolved. ...Patients with pathogenic (or likely pathogenic) variants were considered genotype positive ( …
BACKGROUND: The genetic basis of hypertrophic cardiomyopathy (HCM) is complex, and the relationship between genotype status an …
The evolving paradigm and current perception of hypertrophic cardiomyopathy: Implications for management.
Del Franco A, Menale S, Chiti C, Biagioni G, Tomberli A, Zampieri M, Olivotto I. Del Franco A, et al. Prog Cardiovasc Dis. 2023 Sep-Oct;80:8-13. doi: 10.1016/j.pcad.2023.08.002. Epub 2023 Aug 10. Prog Cardiovasc Dis. 2023. PMID: 37572782 Review.
Recent evidence from imaging and genetic screening studies has clearly shown that hypertrophic cardiomyopathy (HCM) is more common than initially perceived, emphasizing the need to reassess its associated clinical and social burden. ...Furthermore, a broader perspec …
Recent evidence from imaging and genetic screening studies has clearly shown that hypertrophic cardiomyopathy (HCM) is more co …
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside.
Palandri C, Santini L, Argirò A, Margara F, Doste R, Bueno-Orovio A, Olivotto I, Coppini R. Palandri C, et al. Drugs. 2022 Jun;82(8):889-912. doi: 10.1007/s40265-022-01728-w. Epub 2022 Jun 13. Drugs. 2022. PMID: 35696053 Free PMC article. Review.
Hypertrophic cardiomyopathy (HCM), the most common inherited heart disease, is still orphan of a specific drug treatment. The erroneous consideration of HCM as a rare disease has hampered the design and conduct of large, randomized trials in the last 50 years, and m …
Hypertrophic cardiomyopathy (HCM), the most common inherited heart disease, is still orphan of a specific drug treatment. The …
Management and outcomes of hypertrophic cardiomyopathy in young adults.
Baron É, Karam N, Donal E, Puscas T, Mirabel M, Bacher A, Wahbi K, Mazzella JM, Jeunemaitre X, Reant P, Hagège A; REMY, GEREMY working groups of the French Society of Cardiology. Baron É, et al. Arch Cardiovasc Dis. 2021 Jun-Jul;114(6-7):465-473. doi: 10.1016/j.acvd.2020.12.006. Epub 2021 Mar 17. Arch Cardiovasc Dis. 2021. PMID: 33744178 Free article.
BACKGROUND: Management of young adults with hypertrophic cardiomyopathy (HCM) is challenging. AIMS: To evaluate the profile of young adults (16-25 years) with HCM included in the French prospective HCM registry. ...RESULTS: At baseline, among 61 patients (20.53.0 ye …
BACKGROUND: Management of young adults with hypertrophic cardiomyopathy (HCM) is challenging. AIMS: To evaluate the profile of …
Atrial Fibrillation in Hypertrophic Cardiomyopathy: Evidence-based Review About Mechanism, Complications and Management.
Arunachalam K, Maan A, Chu A. Arunachalam K, et al. Crit Pathw Cardiol. 2020 Jun;19(2):87-89. doi: 10.1097/HPC.0000000000000210. Crit Pathw Cardiol. 2020. PMID: 32011359 Review.
Hypertrophic cardiomyopathy (HCM) is 1 of the most frequent genetic cardiovascular diseases affecting 1 out of every 500 individuals in general population. Atrial Fibrillation incidences were 3.8% per 100 patients per year and overall prevalence among HCM pat …
Hypertrophic cardiomyopathy (HCM) is 1 of the most frequent genetic cardiovascular diseases affecting 1 out of every 500 indiv …
176 results